Research Says Australia Policy Keeps Generics Costlier Than In U.S.
This article was originally published in PharmAsia News
Although branded drugs are cheaper in Australia, Aussies pay more than their U.S. counterparts for generic drugs, according to new research. The Deakin University researcher blamed the difference on the lack of price competition in Australia because government policy requires drug makers to disclose ahead of time when they are going to reduce prices. As a result of that policy, Liliana Bulfone said, generics marketers in Australia resist being the first to reduce prices, so they tend not to do so until a competitor acts. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.